Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
about
Surrogate endpoints in global health research: still searching for killer apps and silver bullets?Knowledge Translation in Healthcare - Towards Understanding its True Complexities Comment on "Using Complexity and Network Concepts to Inform Healthcare Knowledge Translation".Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.A randomised controlled trial is not a pilot trial simply because it uses a surrogate endpointSurrogate endpoints in advanced sarcoma trials: a meta-analysisFrom validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting
P2860
Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
description
2017 nî lūn-bûn
@nan
2017 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Surrogate endpoints in oncolog ...... d are they currently overused?
@ast
Surrogate endpoints in oncolog ...... d are they currently overused?
@en
type
label
Surrogate endpoints in oncolog ...... d are they currently overused?
@ast
Surrogate endpoints in oncolog ...... d are they currently overused?
@en
prefLabel
Surrogate endpoints in oncolog ...... d are they currently overused?
@ast
Surrogate endpoints in oncolog ...... d are they currently overused?
@en
P2860
P1433
P1476
Surrogate endpoints in oncolog ...... d are they currently overused?
@en
P2093
Robert Kemp
Vinay Prasad
P2860
P2888
P356
10.1186/S12916-017-0902-9
P407
P577
2017-07-21T00:00:00Z
P6179
1090559553